Presenters at the all-virtual San Antonio Breast Cancer Symposium (SABCS; December 8–11, 2020) reported the latest findings in breast cancer research. NEJM Journal Watch Oncology and Hematology Editor-in-Chief Dr. William Gradishar summarizes and provides perspective for several of the key studies. For access to the abstracts, please visit the Abstract Viewer.
CDK4/6 Inhibitors for Early-Stage ER+ Breast Cancer
The role of CDK4/6 inhibitors as a component of adjuvant therapy for early-stage, ER+ breast cancer is evolving with the reporting of important randomized trials evaluating all three of the currently available CDK4/6 inhibitors.
At the virtual 2020 ESMO meeting (NEJM JW Oncol Hematol Nov 2020), the PALLAS study in high-risk patients wit…
Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)